Bladder Cancer: Diagnosis and Evaluation: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
'''See [[CUA: Muscle-invasive Bladder Cancer (2019)|2019 CUA Muscle-Invasive Bladder Cancer Guideline Notes]]''' | '''See [[CUA: Muscle-invasive Bladder Cancer (2019)|2019 CUA Muscle-Invasive Bladder Cancer Guideline Notes]]''' | ||
== Stage at Diagnosis == | |||
* United States (SEER)[https://seer.cancer.gov/statistics-network/explorer/application.html?site=71&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2] | |||
** In situ: 48% | |||
** Localized: 35% | |||
** Regional: 7% | |||
** Distant: 5% | |||
** Unstaged: 5% | |||
== History and Physical exam == | == History and Physical exam == | ||